title: Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas.
abstract: BACKGROUND
  The biologic parameters, DNA ploidy and proliferative activity, have been suggested as prognostic factors in non-Hodgkin's lymphoma (NHL). However, reports on the prognostic importance of these factors in follicle center cell-derived (FCC) centroblastic/centrocytic (CB/CC) NHL patients with long follow-up are scarce.
  
  
  METHODS
  Apoptotic fractions were quantified in 60 patients with CB/CC NHL by in situ labeling of DNA strand breaks in nuclei [TdT-mediated dUTP/dATP in situ 3'OH--end labeling (TUNEL)]. The findings were related to S-phase and MIB-1 counts, DNA ploidy, and clinical outcome.
  
  
  RESULTS
  In CB/CC NHL, the percentages of proliferating and apoptotic cells were lower than in reactive germinal centers (GC; P < 0.05; mean, 0.188 vs 3.263% and 19.05 vs. 69.4% for TUNEL and MIB-1 positive cells in CB/CC and GC, respectively). Significantly higher percentages of MIB-1 and TUNEL positive cells were observed in patients with complete remission when compared with the partial remission / no response group (P < 0.01). The size of proliferative and apoptotic fractions did not correlate with the overall survival of the patients. However, follicular and diffuse growth pattern, elevated serum lactic dehydrogenase, advanced stage, and age indicated a lower probability of 5- and 10-year survival.
  
  
  CONCLUSIONS
  The investigation of proliferative and apoptotic fractions in FCC lymphomas may help to define groups of patients to who would benefit from aggressive, high dose therapy protocols and patients to whom less aggressive strategies can be applied safely.
authors.affiliation: Department of Pathology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Czader
authors.forename: J
authors.initials: J
authors.lastname: Mazur
authors.forename: M
authors.initials: M
authors.lastname: Pettersson
authors.forename: J
authors.initials: J
authors.lastname: Liliemark
authors.forename: M
authors.initials: M
authors.lastname: Strömberg
authors.forename: B
authors.initials: B
authors.lastname: Christensson
authors.forename: B
authors.initials: B
authors.lastname: Tribukait
authors.forename: G
authors.initials: G
authors.lastname: Auer
authors.forename: A
authors.initials: A
authors.lastname: Ost
authors.forename: A
authors.initials: A
authors.lastname: Porwit
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000502:physiology*; D002455:Cell Division; D004247:DNA / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D018858:Germinal Center / Q000473:pathology*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D004247:DNA